Nyxoah S.A. (NYXH)
USD 6.12
(1.75%)
USD 6.12
(1.75%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 12.7 Million EUR | 6.92% |
| 2022 | 11.88 Million EUR | 1.77% |
| 2021 | 11.67 Million EUR | 1.17% |
| 2020 | 11.54 Million EUR | 34.2% |
| 2019 | 8.59 Million EUR | 47.88% |
| 2018 | 5.81 Million EUR | 10.47% |
| 2017 | 5.26 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 12.74 Million EUR | 0.34% |
| 2024 Q2 | 12.74 Million EUR | -0.03% |
| 2023 Q1 | 12.59 Million EUR | 5.99% |
| 2023 Q3 | 12.95 Million EUR | 1.73% |
| 2023 Q4 | 12.7 Million EUR | -1.93% |
| 2023 Q2 | 12.73 Million EUR | 1.11% |
| 2023 FY | 12.7 Million EUR | 6.92% |
| 2022 Q1 | 11.81 Million EUR | 1.18% |
| 2022 FY | 11.88 Million EUR | 1.77% |
| 2022 Q4 | 11.88 Million EUR | -2.96% |
| 2022 Q3 | 12.24 Million EUR | -0.3% |
| 2022 Q2 | 12.28 Million EUR | 3.96% |
| 2021 Q4 | 11.67 Million EUR | 0.0% |
| 2021 FY | 11.67 Million EUR | 1.17% |
| 2021 Q2 | 11.84 Million EUR | 1.83% |
| 2021 Q1 | 11.62 Million EUR | 0.75% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 Q4 | 11.54 Million EUR | 4.27% |
| 2020 Q3 | 11.06 Million EUR | 10.46% |
| 2020 Q2 | 10.01 Million EUR | 0.0% |
| 2020 FY | 11.54 Million EUR | 34.2% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 Q4 | 8.59 Million EUR | 4.12% |
| 2019 Q3 | 8.25 Million EUR | 0.0% |
| 2019 FY | 8.59 Million EUR | 47.88% |
| 2018 FY | 5.81 Million EUR | 10.47% |
| 2017 FY | 5.26 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 85.7 Million USD | 85.177% |
| AngioDynamics, Inc. | 5.91 Million USD | -114.812% |
| AtriCure, Inc. | 74.49 Million USD | 82.946% |
| Avinger, Inc. | 15.39 Million USD | 17.48% |
| Azenta, Inc. | 60.43 Million USD | 78.979% |
| BioLife Solutions, Inc. | 42.69 Million USD | 70.242% |
| The Cooper Companies, Inc. | 2.56 Billion USD | 99.506% |
| Daxor Corporation | 755.65 Thousand USD | -1581.182% |
| Ekso Bionics Holdings, Inc. | 7.16 Million USD | -77.232% |
| Femasys Inc. | 6.7 Million USD | -89.587% |
| GlucoTrack, Inc. | 196 Thousand USD | -6381.633% |
| Harvard Bioscience, Inc. | 42.77 Million USD | 70.299% |
| Hologic, Inc. | 2.53 Billion USD | 99.499% |
| ICU Medical, Inc. | 1.7 Billion USD | 99.255% |
| Intuitive Surgical, Inc. | 89.8 Million USD | 85.853% |
| KORU Medical Systems, Inc. | 4.44 Million USD | -185.797% |
| LeMaitre Vascular, Inc. | 19.09 Million USD | 33.469% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Masimo Corporation | 970 Million USD | 98.69% |
| Microbot Medical Inc. | 231 Thousand USD | -5399.567% |
| Meihua International Medical Technologies Co., Ltd. | 7.33 Million USD | -73.288% |
| Merit Medical Systems, Inc. | 891.35 Million USD | 98.575% |
| Nephros, Inc. | 1.83 Million USD | -591.939% |
| NovoCure Limited | 596.24 Million USD | 97.869% |
| NEXGEL, Inc. | 2.79 Million USD | -354.039% |
| NEXGEL, Inc. | 2.79 Million USD | -354.039% |
| Singular Genomics Systems, Inc. | 75.28 Million USD | 83.126% |
| OraSure Technologies, Inc. | 13.5 Million USD | 5.924% |
| Pro-Dex, Inc. | 13.54 Million USD | 6.223% |
| Pulse Biosciences, Inc. | 9.14 Million USD | -38.933% |
| Predictive Oncology Inc. | 2.85 Million USD | -344.691% |
| Precision Optics Corporation, Inc. | 3.43 Million USD | -269.898% |
| QuidelOrtho Corporation | 2.61 Billion USD | 99.514% |
| Repligen Corporation | 711.8 Million USD | 98.215% |
| Sanara MedTech Inc. | 11.79 Million USD | -7.733% |
| STAAR Surgical Company | 35.83 Million USD | 64.548% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| Utah Medical Products, Inc. | 342 Thousand USD | -3614.62% |
| DENTSPLY SIRONA Inc. | 2.29 Billion USD | 99.447% |
| Jin Medical International Ltd. | 4.11 Million USD | -208.874% |